Skip to main content
    N

    Novocure Ltd (NVCR)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $11.30
    -0.53 (-4.48%)

    Market Cap: $1.38B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Novocure Ltd (NVCR) Earnings: Report Dates and Results

    Updated Oct 29, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, Novocure reported EPS of -$0.09, above the -$0.21 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    59%(23/39)
    Avg Surprise
    -2.59%
    Streak
    2 Q

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus-$0.24
    Range-$0.30 - -$0.20
    9 analysts
    Revenue Consensus
    $193.67M
    Range$183.24M - $200.88M
    9 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus-$0.20
    Range-$0.25 - -$0.13
    4 analysts
    EPS Revisions
    4
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.22+9.3%
    60d ago-$0.22+9.3%
    30d ago-$0.22+9.3%
    7d ago-$0.19-2.6%
    Current-$0.20
    Revenue Consensus
    $189.43M
    Range$184.80M - $192.80M
    3 analysts

    Next Report

    NVCR's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    NVCR Earnings Call

    The latest NVCR earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, NVCR beat 23 and missed 16. Revenue for the quarter ended Sep 30, 2026 was $193.40M, up 15.7% from $167.20M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.09-$0.21-$0.31 - -$0.14+57.14%BeatN/A71 up, 0 downOct 29, 2026$193.40M
    Jun 30, 2026-$0.13-$0.30-$0.40 - -$0.23+56.67%BeatN/A65 up, 2 downJul 23, 2026$183.58M
    Mar 31, 2026-$0.62-$0.51-$0.83 - -$0.34-21.57%MissN/A70 up, 2 downApr 30, 2026$174.06M
    Dec 31, 2025-$0.22-$0.41-$0.47 - -$0.30+46.34%BeatN/A72 up, 4 downFeb 26, 2026$174.35M
    Sep 30, 2025-$0.33-$0.42-$0.48 - -$0.37+21.43%BeatN/A83 up, 3 downOct 30, 2025$167.20M
    Jun 30, 2025-$0.36-$0.39-$0.46 - -$0.36+7.69%BeatN/A76 up, 0 downJul 24, 2025$158.81M
    Mar 31, 2025-$0.31-$0.46-$0.74 - -$0.26+32.61%BeatN/A70 up, 0 downApr 24, 2025$154.99M
    Dec 31, 2024-$0.61-$0.36-$0.44 - -$0.27-69.44%MissN/A73 up, 0 downFeb 27, 2025$161.27M
    Sep 30, 2024-$0.28-$0.33-$0.41 - -$0.23+15.15%BeatN/A70 up, 1 downOct 30, 2024$155.09M
    Jun 30, 2024-$0.31-$0.40-$0.46 - -$0.30+22.50%BeatN/A60 up, 0 downJul 25, 2024$150.36M
    Mar 31, 2024-$0.36-$0.42-$0.52 - -$0.36+14.29%BeatN/A70 up, 0 downMay 2, 2024$138.50M
    Dec 31, 2023-$0.45-$0.52-$0.61 - -$0.47+13.46%BeatN/A70 up, 0 downFeb 22, 2024$133.78M
    Sep 30, 2023-$0.46-$0.52-$0.57 - -$0.43+11.54%BeatN/A60 up, 0 downOct 26, 2023$127.32M
    Jun 30, 2023-$0.54-$0.50-$0.53 - -$0.46-8.00%MissN/A50 up, 1 downJul 27, 2023$126.05M
    Mar 31, 2023-$0.50-$0.34-$0.45 - -$0.22-47.06%MissN/A80 up, 0 downMay 4, 2023$122.18M
    Dec 31, 2022-$0.36-$0.30-$0.45 - -$0.24-20.00%MissN/A80 up, 0 downFeb 23, 2023$128.43M
    Sep 30, 2022-$0.25-$0.26-$0.39 - -$0.13+3.85%BeatN/A70 up, 0 downOct 27, 2022$131.00M
    Jun 30, 2022-$0.23-$0.14-$0.25 - -$0.06-64.29%MissN/A90 up, 0 downJul 28, 2022$140.87M
    Mar 31, 2022-$0.04-$0.18-$0.30 - -$0.10+77.78%BeatN/A80 up, 0 downApr 28, 2022$137.55M
    Dec 31, 2021-$0.25-$0.10-$0.14 - -$0.07-150.00%Miss-725.0%80 up, 0 downFeb 24, 2022$133.21M
    Sep 30, 2021-$0.13-$0.06-$0.15 - $0.00-116.67%Miss-244.4%90 up, 1 downOct 28, 2021$133.61M
    Jun 30, 2021-$0.14$0.01-$0.03 - $0.05N/AN/A-800.0%9N/AJul 29, 2021$133.52M
    Mar 31, 2021-$0.04$0.01-$0.02 - $0.06-500.00%Miss-200.0%9N/AApr 29, 2021$134.69M
    Dec 31, 2020$0.04$0.12$0.07 - $0.20-66.67%Miss0.0%9N/AFeb 25, 2021$143.95M
    Sep 30, 2020$0.09$0.04$0.01 - $0.06+125.00%Beat+350.0%9N/AOct 29, 2020$132.66M
    Jun 30, 2020$0.02$0.01-$0.03 - $0.04+100.00%BeatN/A8N/AJul 30, 2020$115.92M
    Mar 31, 2020$0.04$0.02-$0.05 - $0.07+100.00%BeatN/A7N/AApr 30, 2020$101.83M
    Dec 31, 2019$0.04$0.02-$0.05 - $0.05+100.00%BeatN/A7N/AFeb 27, 2020$99.23M
    Sep 30, 2019$0.02-$0.04-$0.10 - $0.02+150.00%BeatN/A6N/AOct 31, 2019$92.06M
    Jun 30, 2019-$0.01-$0.06-$0.13 - -$0.01+83.33%BeatN/A7N/AJul 25, 2019$86.71M
    Mar 31, 2019-$0.13-$0.15-$0.27 - -$0.04+13.33%BeatN/A6N/AMay 2, 2019$73.31M
    Dec 31, 2018-$0.17-$0.13-$0.17 - -$0.09-30.77%MissN/A5N/AFeb 28, 2019$69.67M
    Sep 30, 2018-$0.13-$0.14-$0.17 - -$0.12+7.14%BeatN/A5N/AOct 25, 2018$64.76M
    Jun 30, 2018-$0.17-$0.16-$0.19 - -$0.11-6.25%MissN/A5N/AJul 26, 2018$61.51M
    Mar 31, 2018-$0.23-$0.13-$0.15 - -$0.11-76.92%MissN/A5N/AApr 26, 2018$52.13M
    Dec 31, 2017-$0.12-$0.11-$0.18 - -$0.03-9.09%MissN/A6N/AFeb 22, 2018$53.66M
    Sep 30, 2017-$0.13-$0.14-$0.23 - $0.02+7.14%BeatN/A6N/AOct 26, 2017$50.11M
    Jun 30, 2017-$0.24-$0.22-$0.26 - -$0.16-9.09%MissN/A5N/AJul 27, 2017$38.38M
    Mar 31, 2017-$0.21-$0.20N/A-5.00%MissN/AN/AN/AApr 27, 2017$34.88M
    Dec 31, 2016-$0.26-$0.39N/A+33.33%BeatN/AN/AN/AFeb 23, 2017$30.24M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.22, after -$1.56 the year before. It was -$1.47 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.22N/A
    Dec 31, 2024-$1.56N/A
    Dec 31, 2023-$1.95N/A
    Dec 31, 2022-$0.88N/A
    Dec 31, 2021-$0.56-394.7%
    Dec 31, 2020$0.19N/A
    Dec 31, 2019-$0.08N/A
    Dec 31, 2018-$0.70N/A
    Dec 31, 2017-$0.70N/A
    Dec 31, 2016-$1.47N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,300 words across 11 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20265,28911
    2026Q2Jun 30, 20265,39012
    2026Q1Mar 31, 20265,73313
    2025Q4Dec 31, 20254,30710
    2025Q3Sep 30, 20256,57211
    2025Q2Jun 30, 20256,77213
    2025Q1Mar 31, 20257,01713
    2024Q4Dec 31, 20245,53911

    2026Q3 Earnings Call

    Opening remarks

    Adam Daney Investor Relations Good morning, and thank you for joining us to review Novocure's third quarter 2026 performance. I am joined on the phone today by our Executive Chairman, Bill Doyle; CEO, Frank Leonard; Chief Innovation and Medical Officer, Uri Weinberg; and CFO, Christoph Brackmann. For your reference, slides accompanying this earnings release can be found on our website, www.novocure.com, on the Investor Relations page under Quarterly Results. Before we start, I would like to remind you that our discussions during this conference call will include forward-looking statements. Actual results could differ materially from those projected in these statements. These statements involve a number of risks and uncertainties, some of which are beyond our control and are described from time to time in our SEC filings. We do not intend to update publicly any forward-looking statement except as required by law. Where appropriate, we will refer to non-GAAP financial measures to evaluate our business, and specifically adjusted EBITDA, a measure of earnings before interest, taxes, depreciation, amortization, and share-based compensation. We believe adjusted EBITDA is an important metric as it removes the impact of earnings attributable to capital structure, tax rate, and material noncash items, and best reflects the financial value generated by our business. We do not provide forward-looking guidance for adjusted EBITDA on a GAAP basis due to the inability to predict share-based compensation expenses contained in the reconciled GAAP measure, net income, without reasonable efforts. Reconciliations of non-GAAP to GAAP financial measures are included in our press release, earnings slides, and in our Form 10-Q filed with the SEC today. These materials can be accessed from the Investor Relations page of our website. Following our prepared remarks, we will open the line for questions. I will now turn the call over to our Executive Chairman, Bill Doyle.

    William F. Doyle Executive Chairman Thank you, Adam. This morning, Novocure reported results for the third quarter of 2026. This quarter was marked by solid execution, with continued momentum in our Optune Gio business and our promising launch of Optune Lua in Japan. We reached a record number of active patients on therapy, generated record-high quarterly net revenue, and made strong progress on our path to profitability. We experienced headwinds in our Optune Pax launch this quarter, but remain committed to establishing TTFields therapy in the evolving PDAC standard of care. As we enter the final months of the year, we are on track to achieve our 2026 goals, and we believe we are well positioned to drive this positive momentum into 2027. I will begin this morning with a review of our Optune Gio and Optune Maya programs.

    Frequently Asked Questions About NVCR

    Did NVCR beat earnings estimates last quarter?

    Yes. Novocure reported EPS of -$0.09 for the quarter ended Sep 30, 2026, above the -$0.21 estimate, a 57.14% surprise.

    What EPS do analysts expect from NVCR next quarter?

    The consensus EPS estimate for Novocure for the quarter ending Dec 31, 2026 is -$0.24 from 9 analysts, with estimates from -$0.30 to -$0.20.

    How often does NVCR beat earnings estimates?

    Novocure beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +16.36%.